




## FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

DAVID PARKER  
PARTNER  
DPARKER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3055  
TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

March 12, 2004

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
March 12, 2004 Date	 David L. Parker

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450


Re: SN 08/726,211 entitled "*Inhibition of Bcl-2 Protein Expression by Liposomal Antisense Oligodeoxynucleotides*" by Tormo et al.  
Our ref: UTXC:504      Client ref: MDA96-020

Commissioner:

Enclosed for filing in the above-referenced patent application are the following:

- (1) Response to Official Action Dated December 12, 2003 (with attached copy of pending claims in co-pending application Serial No. 09/381,747); and
- (2) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

It is believed that no fees are due. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/UTXC:504.

  
Very truly yours,  
David Parker  
Reg. No. 32,165

DLP/lb  
Enclosures

25394778.1 / 10016654



CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
March 12, 2004 Date	 David L. Parker

**PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Mar Tormo

Ana M. Tari

Gabriel Lopez-Berestein

Group Art Unit: 1636

Examiner: D. Sullivan

Serial No.: 08/726,211

Atty. Dkt. No.: UTXC:504

Filed: October 4, 1996

For: INHIBITION OF BCL-2 PROTEIN  
EXPRESSION BY LIPOSOMAL  
ANTISENSE  
OLIGODEOXYNUCLEOTIDES

**RESPONSE TO OFFICIAL ACTION DATED DECEMBER 12, 2003**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This paper is submitted in response to the Office Action dated December 12, 2003 for which the three-month date for response is March 12, 2003.

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski LLP Account No. 50-1212/UTXC:504.

Reconsideration of the application is respectfully requested.